```
=> d his

     (FILE 'HOME' ENTERED AT 15:31:53 ON 08 OCT 2002)

     FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:32:06 ON 08 OCT
     2002
L1          2255 S REPLICATION(3A)DEFICIENT(4A)ADENOVIR?
L2         13390 S E1A OR E1B
L3            80 S L1 AND L2
L4        403791 S CYTOKINE OR INTERLEUKINE
L5        665117 S CYTOKINE OR INTERLEUKIN
L6             2 S L3 AND L5
L7           278 S L5 AND L1
L8             2 DUP REM L6 (0 DUPLICATES REMOVED)
L9           186 S L1(S)L5
L10           34 S L1(6A)L5
L11           14 DUP REM L10 (20 DUPLICATES REMOVED)
L12           74 DUP REM L9 (112 DUPLICATES REMOVED)

=> d bib ab 1-2 l8

L8   ANSWER 1 OF 2     MEDLINE
AN   2002118211     MEDLINE
DN   21834180   PubMed ID: 11844116
TI   Infection of replication-deficient adenoviral
     vector enhances interleukin-8 production in small airway
     epithelial cells more than in large airway epithelial cells.
AU   Kodama Y; Setoguchi Y; Fukuchi Y
CS   Department of Respiratory Medicine, Juntendo University, School of
     Medicine, 2-1-1 Hongo, Bunkyo-Ku, Tokyo 113-8421, Japan.
SO   RESPIROLOGY, (2001 Dec) 6 (4) 271-9.
     Journal code: 9616368. ISSN: 1323-7799.
CY   Australia
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200203
ED   Entered STN: 20020221
     Last Updated on STN: 20020307
     Entered Medline: 20020306
AB   OBJECTIVE: In clinical trials or experiments of gene therapy, airway
     administration of an adenoviral-based vector (E1A-deleted)
     elicits a dose-dependent inflammatory response with limitation in the
     duration of transgene expression. The purpose of this study was to
     evaluate the possibility that the adenoviral-based vector directly
     enhances IL-8 production independent of adenoviral E1A in normal
     human airway epithelial cells and to examine the different responses
     between primary human bronchial epithelial cells (HBE) and primary human
     small airway epithelial cells (HSAE) in production of IL-8 following
     exposure to an adenovirus vector. METHODOLOGY: Interleukin
     (IL)-8 levels were evaluated in the culture medium from HBE and HSAE
     treated with increasing doses of E1A-deleted adenoviral vector
     contained the Escherichia coli LacZ reporter gene (AdCMVLacZ). To clarify
     the mechanism of enhancing IL-8 production in airway epithelial cells by
     infection with adenovirus vector, alphavbeta5 agonistic antibody as an
     analogue of adenoviral capsid and adenoviral capsid vector denatured by
     exposure to ultraviolet (UV) light were used in the present study.
     RESULTS: Inoculation of HBE with AdCMVLacZ at a multiplicity of infection
     (MOI) of between 1 and 200 resulted in a dose-dependent expression of
```

LacZ, and maximal expression was observed at a MOI of 100. In contrast, inoculation of HSAE with AdCMVLacZ resulted in maximum expression of LacZ at a MOI of 10. **Interleukin**-8 levels in culture media from the same experiments revealed significantly greater production of IL-8 in HSAE inoculated with AdCMVLacZ at a MOI of 50, compared to HBE under the same conditions. The capsid-denatured adenoviral vector did not enhance IL-8 production, and alphavbeta5 agonistic antibody induced IL-8 enhancement. CONCLUSION: These results suggest that the adenoviral vector directly induces the expression of airway epithelial inflammatory **cytokines** in the pathogenesis of inflammation and that small airway cells have a greater affinity for adenovirus than other airway epithelial cells.

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2002 ACS
AN 1999:359676 CAPLUS
DN 131:14853
TI Construction of modified SV40 viral vectors for gene delivery
IN Fang, Bingliang; Highlander, Steven L.; Casement, Kevin S.; Roth, Jack A.
PA Board of Regents, the University of Texas System, USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9927123	A2	19990603	WO 1998-US25225	19981125
	WO 9927123	A3	19990812		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9915369	A1	19990615	AU 1999-15369	19981125
PRAI	US 1997-978539		19971126		
	WO 1998-US25225		19981125		

AB The present invention provides SV40-based viral vectors for use in the delivery of genes to target cells. The unique combination of multiple viral systems provides for vectors with increased carrying capacity and extended host range when compared to normal SV40 vectors. The infectious SV40 viral vector comprises (1) providing an SV40 viral vector comprising an SV40 origin of replication and an expression region operably linked to a first promoter active in eukaryotic cells, wherein said vector lacks SV40 coding sequences; (b) providing a **replication-deficient adenoviral** helper virus having the late region of JC virus or BK virus under the control of a second promoter active in eukaryotic cells; (c) infecting host cells with said adenoviral helper virus; (d) transfecting said host cells with said vector; (e) culturing said host cells for a period of time sufficient to permit said vector to replicate and be packaged; and (f) harvesting said packaged vector in an infectious form. The first and second promoter may be a cytomegalovirus immediate-early or SV40 immediate-early promoter. The host cells may express a polyomavirus large T antigen, for example, like COS-7 cells. The adenoviral helper virus may lack E1 regions. Uses for the vectors include the expression of proteins in vitro and in vivo.

=> d au ti so 1-14 l11

L11 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2002 ACS
AU von der Thuesen, Jan H.; Kuiper, Johan; Fekkes, Madelon L.; de Vos, Paula;
van Berkel, Theo J. C.; Biessen, Erik A. L.
TI Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr -/- mice
SO FASEB Journal (2001), 15(14), 2730-2732, 10.1096/fj.01-0483fje
CODEN: FAJOEC; ISSN: 0892-6638

L11 ANSWER 2 OF 14 MEDLINE DUPLICATE 1
AU Coates P T; Krishnan R; Kireta S; Johnston J; Russ G R
TI Human myeloid dendritic cells transduced with an adenoviral interleukin-10
gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice.
SO GENE THERAPY, (2001 Aug) 8 (16) 1224-33.
Journal code: 9421525. ISSN: 0969-7128.

L11 ANSWER 3 OF 14 MEDLINE DUPLICATE 2
AU Inoue S; Suzuki M; Nagashima Y; Suzuki S; Hashiba T; Tsuburai T; Ikehara K; Matsuse T; Ishigatsubo Y
TI Transfer of heme oxygenase 1 cDNA by a **replication-deficient adenovirus** enhances **interleukin** 10
production from alveolar macrophages that attenuates lipopolysaccharide-induced acute lung injury in mice.
SO HUMAN GENE THERAPY, (2001 May 20) 12 (8) 967-79.
Journal code: 9008950. ISSN: 1043-0342.

L11 ANSWER 4 OF 14 MEDLINE DUPLICATE 3
AU Cua D J; Hutchins B; LaFace D M; Stohlman S A; Coffman R L
TI Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis.
SO JOURNAL OF IMMUNOLOGY, (2001 Jan 1) 166 (1) 602-8.
Journal code: 2985117R. ISSN: 0022-1767.

L11 ANSWER 5 OF 14 MEDLINE
AU Kodama Y; Setoguchi Y; Fukuchi Y
TI Infection of **replication-deficient adenoviral** vector enhances **interleukin**-8 production in small airway epithelial cells more than in large airway epithelial cells.
SO RESPIROLOGY, (2001 Dec) 6 (4) 271-9.
Journal code: 9616368. ISSN: 1323-7799.

L11 ANSWER 6 OF 14 MEDLINE DUPLICATE 4
AU Yoshikawa K; Kajiwara K; Ideguchi M; Uchida T; Ito H
TI Immune gene therapy of experimental mouse brain tumor with adenovirus-mediated gene transfer of murine interleukin-4.
SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (2000 Apr) 49 (1) 23-33.
Journal code: 8605732. ISSN: 0340-7004.

L11 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2002 ACS
AU Liu, Lin; Luo, Chengji; Yuan, Liangping; Su, Yongping
TI Construction and identification of **replication-deficient** mouse **interleukin**-3 recombinant **adenoviruses**
SO Mianyixue Zazhi (1999), 15(4), 242-244
CODEN: MIZAED; ISSN: 1000-8861

L11 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2002 ACS

AU Divino, Celia M.; Yang, Wen; Chen, Shu-Hsia; Woo, Savio L. C.; Brower, Steven T.
TI Adenovirus-mediated interleukin-12 gene therapy of metastatic breast cancer
SO Surgical Forum (1998), 49, 410-412
CODEN: SUFOAX; ISSN: 0071-8041

L11 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 5
AU Zhang, Weiping; Cao, Xuetao; Hamada, Hirofumi
TI Preparation and identification of **replication-deficient** human **interleukin** 2 recombinant **adenoviruses**
SO Zhonghua Weishengwuxue He Mianyixue Zazhi (1998), 18(2), 152-156
CODEN: ZWMZDP; ISSN: 0254-5101

L11 ANSWER 10 OF 14 MEDLINE DUPLICATE 6
AU Thibault V; Terlain B; Graham F L; Gauldie J
TI Construction and characterization of a **replication-deficient adenovirus** expressing rat-soluble **interleukin**-6 receptor.
SO MOLECULAR MEDICINE, (1997 Aug) 3 (8) 519-29.
Journal code: 9501023. ISSN: 1076-1551.

L11 ANSWER 11 OF 14 MEDLINE DUPLICATE 7
AU Amin R; Wilmott R; Schwarz Y; Trapnell B; Stark J
TI **Replication-deficient adenovirus** induces expression of **interleukin**-8 by airway epithelial cells in vitro.
SO HUMAN GENE THERAPY, (1995 Feb) 6 (2) 145-53.
Journal code: 9008950. ISSN: 1043-0342.

L11 ANSWER 12 OF 14 MEDLINE DUPLICATE 8
AU Cordier L; Duffour M T; Sabourin J C; Lee M G; Cabannes J; Ragot T; Perricaudet M; Haddada H
TI Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene.
SO GENE THERAPY, (1995 Jan) 2 (1) 16-21.
Journal code: 9421525. ISSN: 0969-7128.

L11 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2002 ACS
IN Perricaudet, Michel; Ragot, Thierry; Finerty, Susan; Morgan, Andrew J.
TI Defective recombinant adenoviruses expressing characteristic Epstein-Barr virus (EBV) proteins, and use for vaccines against EBV-caused diseases
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

L11 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002 ACS
IN Crystal, Ronald G.
TI Adenovirus-mediated transfer of genes to the gastrointestinal tract
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

=> d bib 13 14 l11

L11 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1993:647975 CAPLUS
DN 119:247975
TI Defective recombinant adenoviruses expressing characteristic Epstein-Barr virus (EBV) proteins, and use for vaccines against EBV-caused diseases
IN Perricaudet, Michel; Ragot, Thierry; Finerty, Susan; Morgan, Andrew J.

PA Centre National de la Recherche Scientifique, Fr.; Cancer Research Campaign
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9319092	A1	19930930	WO 1992-FR256	19920319
	W: AU, CA, JP, US				
	AU 9216480	A1	19931021	AU 1992-16480	19920319
PRAI	WO 1992-FR256		19920319		

L11 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002 ACS
AN 1993:205248 CAPLUS
DN 118:205248
TI Adenovirus-mediated transfer of genes to the gastrointestinal tract
IN Crystal, Ronald G.
PA United States Dept. of Health and Human Services, USA
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9303769	A1	19930304	WO 1992-US7029	19920820
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	AU 9225006	A1	19930316	AU 1992-25006	19920820
	AU 663725	B2	19951019		
	JP 06510665	T2	19941201	JP 1992-504587	19920820
	EP 648271	A1	19950419	EP 1992-918712	19920820
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PRAI	US 1991-747371		19910820		
	WO 1992-US7029		19920820		

=>